Astellas joins forces with Ambrx to develop antibody-drug conjugates

04/8/2013 | Genetic Engineering & Biotechnology News

Astellas Pharma and Ambrx agreed to collaborate in the discovery and development of antibody-drug conjugates for cancer using the latter's site-specific conjugation technology, linkers and drug payloads. Ambrx will get $15 million upfront plus as much as $285 million in milestone fees and sales royalties. The rights to further develop and market the ADCs will go to Astellas.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY